{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:36:17Z","timestamp":1777332977474,"version":"3.51.4"},"posted":{"date-parts":[[2026,2,16]]},"group-title":"HIV\/AIDS","reference-count":74,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,2,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Despite improvements in treatment for people living with HIV (PWH), adherence remains a challenge for many. In this study we aimed to identify preferences for daily pill or long-acting injectable (LAI) antiretroviral therapy (ART) and for possible treatment package features, among PWH enrolled in Ryan White HIV\/AIDS Program Part A (RWPA) Medical Case Management (MCM) programs.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Participants were recruited from six MCM programs from across the New York RWPA eligible metropolitan area (the five boroughs of New York City and Rockland, Putman, and Westchester counties). We developed a discrete choice experiment (DCE) with four attributes: (1) Type of ART Medication (daily pills or LAI), (2) Service Location and Mode, (3) Support, and (4) Rewards. We used an alternative-specific design in which the levels for the last three attributes were dependent on levels within the first (Type of ART). Latent class multinomial logit analysis (LCA) was used for preference estimation and hypothesis-free investigation of preference heterogeneity.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From June 2022 through January 2023, 200 New York RWPA MCM clients completed the DCE. We selected a two-group LCA solution. A majority of participants had a higher preference for LAI regimens compared to daily pills (n=114 [57%] versus n=86 [43%]). Those who preferred LAI ART were younger (median age 49 versus 58.5 years, p&lt;0.001), less likely to identify as straight\/heterosexual (69% versus 82%, p=0.03), and more likely to identify as Latino\/a (54% versus 30%; p&lt;0.001). Preferences for service locations\/mode, supports, and rewards were similar across LCA groups. Participants who preferred LAI ART were more likely to have heard of LAI ART before the survey (59% versus 41%, p=0.012). Overall, only 4% of participants self-reported having tried LAI ART.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Assessing preferences among groups under-represented in clinical trials is essential to effective and equitable real-world implementation of innovative treatment options. Our study found that there were distinct groups that differed in their preferred ART regimen type and that New York RWPA MCM clients had limited familiarity with LAI ART. To inform regimen selection, we began pilot-testing educational materials and a patient-provider decision-making tool in 2023.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.02.13.26346257","type":"posted-content","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T21:10:15Z","timestamp":1771276215000},"source":"Crossref","is-referenced-by-count":1,"title":["HIV Treatment and Program Preferences Among Ryan White Clients in New York City in the Era of Long-Acting Injectable ART: A Discrete Choice Experiment"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5278-3930","authenticated-orcid":false,"given":"Rebecca","family":"Zimba","sequence":"first","affiliation":[{"name":"Institute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY"},{"name":"Department of Epidemiology and Biostatistics, City University of New York, Graduate School of Public Health and Health Policy, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0566-8697","authenticated-orcid":false,"given":"Elizabeth A.","family":"Kelvin","sequence":"additional","affiliation":[{"name":"Institute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY"},{"name":"Department of Epidemiology and Biostatistics, City University of New York, Graduate School of Public Health and Health Policy, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-339X","authenticated-orcid":false,"given":"Sarah","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Institute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7240-9625","authenticated-orcid":false,"given":"Jennifer","family":"Carmona","sequence":"additional","affiliation":[{"name":"Division of Disease Control, New York City Department of Health and Mental Hygiene, Queens, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6202-2043","authenticated-orcid":false,"given":"Tigran","family":"Avoundjian","sequence":"additional","affiliation":[{"name":"Institute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY"},{"name":"Bureau of Hepatitis, HIV, and Sexually Transmitted Infections, New York City Department of Health and Mental Hygiene, Queens, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Connor","family":"Emmert","sequence":"additional","affiliation":[{"name":"Bureau of Hepatitis, HIV, and Sexually Transmitted Infections, New York City Department of Health and Mental Hygiene, Queens, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghan","family":"Peterson","sequence":"additional","affiliation":[{"name":"Bureau of Hepatitis, HIV, and Sexually Transmitted Infections, New York City Department of Health and Mental Hygiene, Queens, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1852-7559","authenticated-orcid":false,"given":"Mary","family":"Irvine","sequence":"additional","affiliation":[{"name":"Bureau of Hepatitis, HIV, and Sexually Transmitted Infections, New York City Department of Health and Mental Hygiene, Queens, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-5386","authenticated-orcid":false,"given":"Denis","family":"Nash","sequence":"additional","affiliation":[{"name":"Institute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY"},{"name":"Department of Epidemiology and Biostatistics, City University of New York, Graduate School of Public Health and Health Policy, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2026021814001023000_2026.02.13.26346257v1.1","doi-asserted-by":"crossref","unstructured":"Office of Infectious Disease and HIV\/AIDS Policy H. What Is Ending the HIV Epidemic in the U.S.? Updated 7\/1\/2022. Accessed 3\/7\/2023, 2023. https:\/\/www.hiv.gov\/federal-response\/ending-the-hiv-epidemic\/overview\/","DOI":"10.1093\/med\/9780197679098.003.0001"},{"key":"2026021814001023000_2026.02.13.26346257v1.2","unstructured":"Centers for Disease Control and Prevention. Ending the HIV Epidemic in the U.S. (EHE). Centers for Disease Control and Prevention (CDC). Accessed February 7, 2024, 2024."},{"key":"2026021814001023000_2026.02.13.26346257v1.3","unstructured":"America\u2019s HIV Epidemic Analysis Dashboard. U.S. Department of Health & Human Services. Accessed February 7, 2024, 2024. https:\/\/ahead.hiv.gov\/?indicator=282&measure=rate&display=table"},{"key":"2026021814001023000_2026.02.13.26346257v1.4","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2016.303088"},{"key":"2026021814001023000_2026.02.13.26346257v1.5","first-page":"e91711","article-title":"Beyond race and place: distal sociological determinants of HIV disparities","volume":"9940","year":"2014","journal-title":"PloS one"},{"key":"2026021814001023000_2026.02.13.26346257v1.6","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-015-1164-1"},{"issue":"4","key":"2026021814001023000_2026.02.13.26346257v1.7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/09540121.2016.1220478","article-title":"Forget about forgetting: structural barriers and severe non-adherence to antiretroviral therapy","volume":"29","year":"2017","journal-title":"AIDS Care"},{"key":"2026021814001023000_2026.02.13.26346257v1.8","unstructured":"FDA. FDA approves Cabenuva and Vocabria for the treatment of HIV-1 infection. US Food and Drug Administration (FDA). Accessed April 4, 2024, 2024. https:\/\/www.fda.gov\/drugs\/human-immunodeficiency-virus-hiv\/fda-approves-cabenuva-and-vocabria-treatment-hiv-1-infection"},{"key":"2026021814001023000_2026.02.13.26346257v1.9","unstructured":"Gallagher A . FDA approves Cabenuva for 2 month dosing to treat HIV-1. Pharmacy Times. Accessed April 4, 2024, 2024. https:\/\/www.pharmacytimes.com\/view\/fda-approves-cabenuva-for-2-month-dosing-to-treat-hiv-1"},{"key":"2026021814001023000_2026.02.13.26346257v1.10","unstructured":"Loria K. Label Changes for Cabenuva, the Long-acting, Injectable HIV Treatment. Medical Economics. Accessed 3\/07\/2023, 2023. https:\/\/www.managedhealthcareexecutive.com\/view\/label-changes-for-cabenuva-the-long-acting-injectable-hiv-treatment"},{"key":"2026021814001023000_2026.02.13.26346257v1.11","unstructured":"Wohl D . The Challenge of Being First: Long-Acting HIV Antiretroviral Therapy Implementation. HealthCentral, LLC. Accessed February 7, 2024, 2024. https:\/\/www.thebodypro.com\/article\/hiv-top-10-2021-long-acting-antiretroviral-therapy"},{"key":"2026021814001023000_2026.02.13.26346257v1.12","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-020-02918-x"},{"key":"2026021814001023000_2026.02.13.26346257v1.13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262926"},{"key":"2026021814001023000_2026.02.13.26346257v1.14","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2019.1622642"},{"issue":"1","key":"2026021814001023000_2026.02.13.26346257v1.15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12954-023-00730-z","article-title":"Perspectives on long-acting injectable HIV antiretroviral therapy at an alternative care site: a qualitative study of people with HIV experiencing substance use and\/or housing instability","volume":"20","year":"2023","journal-title":"Harm Reduction Journal"},{"key":"2026021814001023000_2026.02.13.26346257v1.16","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08071-9"},{"key":"2026021814001023000_2026.02.13.26346257v1.17","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2020.1764906"},{"key":"2026021814001023000_2026.02.13.26346257v1.18","doi-asserted-by":"crossref","unstructured":"de los Rios P , Okoli C , Young B , et al. Treatment aspirations and attitudes towards innovative medications among people living with HIV in 25 countries. Population Medicine. 2020;31(2)","DOI":"10.18332\/popmed\/124781"},{"key":"2026021814001023000_2026.02.13.26346257v1.19","doi-asserted-by":"crossref","unstructured":"Koren D , Fedkiv V , Zhao H , Bettiker R , Tedaldi E , Samuel R . Perceptions of injectable antiretrovirals in an urban HIV clinic. Open Forum Infectious Diseases. 2019;6","DOI":"10.1093\/ofid\/ofz360.2176"},{"key":"2026021814001023000_2026.02.13.26346257v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.idnow.2022.01.010"},{"key":"2026021814001023000_2026.02.13.26346257v1.21","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-022-03964-3"},{"key":"2026021814001023000_2026.02.13.26346257v1.22","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/657961"},{"key":"2026021814001023000_2026.02.13.26346257v1.23","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000158"},{"key":"2026021814001023000_2026.02.13.26346257v1.24","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000159"},{"key":"2026021814001023000_2026.02.13.26346257v1.25","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-016-1663-8"},{"key":"2026021814001023000_2026.02.13.26346257v1.26","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2016.0202"},{"key":"2026021814001023000_2026.02.13.26346257v1.27","doi-asserted-by":"publisher","DOI":"10.1080\/10810730.2016.1261969"},{"key":"2026021814001023000_2026.02.13.26346257v1.28","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S113675"},{"key":"2026021814001023000_2026.02.13.26346257v1.29","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001165"},{"key":"2026021814001023000_2026.02.13.26346257v1.30","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2018.304729"},{"key":"2026021814001023000_2026.02.13.26346257v1.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2005.05049.x"},{"key":"2026021814001023000_2026.02.13.26346257v1.32","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181845589"},{"key":"2026021814001023000_2026.02.13.26346257v1.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2006.00453.x"},{"key":"2026021814001023000_2026.02.13.26346257v1.34","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2009.0288"},{"key":"2026021814001023000_2026.02.13.26346257v1.35","doi-asserted-by":"publisher","DOI":"10.2196\/56892"},{"key":"2026021814001023000_2026.02.13.26346257v1.36","unstructured":"HIV Care and Treatment Program, Bureau of Hepatitis, HIV, and Sexually Transmitted Infections. Unpublished data. New York, NY: New York City Department of Health and Mental Hygiene; 2024."},{"key":"2026021814001023000_2026.02.13.26346257v1.37","unstructured":"HIV Care and Treatment Program, Bureau of Hepatitis, HIV, and Sexually Transmitted Infections. Annual Ryan White Part A Enrollment Report, March 2022 - February 2023. 2024. June 2024."},{"key":"2026021814001023000_2026.02.13.26346257v1.38","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2018.304689"},{"key":"2026021814001023000_2026.02.13.26346257v1.39","unstructured":"Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data \u2013 United States and 6 dependent areas \u2013 2013. HIV Surveillance Supplemental Report 2015;20(2)"},{"issue":"47","key":"2026021814001023000_2026.02.13.26346257v1.40","first-page":"1113","article-title":"Vital signs: HIV diagnosis, care, and treatment among persons living with HIV \u2013 United States, 2011","volume":"63","author":"Centers for Disease Control and Prevention","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026021814001023000_2026.02.13.26346257v1.41","unstructured":"HRSA\/DHHS. Ryan White HIV\/AIDS Program: Program Fact Sheet October 2014. Accessed May 8 2015, http:\/\/hab.hrsa.gov\/abouthab\/files\/programoverviewfacts2014.pdf"},{"key":"2026021814001023000_2026.02.13.26346257v1.42","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu722"},{"key":"2026021814001023000_2026.02.13.26346257v1.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.08.2223"},{"key":"2026021814001023000_2026.02.13.26346257v1.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2010.11.013"},{"key":"2026021814001023000_2026.02.13.26346257v1.45","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2018.0198"},{"key":"2026021814001023000_2026.02.13.26346257v1.46","unstructured":"Orme BK . Getting Started with Conjoint Analysis. Research Publishers, LLC; 2014:234."},{"key":"2026021814001023000_2026.02.13.26346257v1.47","unstructured":"Orme BK , Chrzan K . Becoming an Expert in Conjoint Analysis. Sawtooth Software, Inc; 2017:327."},{"key":"2026021814001023000_2026.02.13.26346257v1.48","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-017-0635-3"},{"key":"2026021814001023000_2026.02.13.26346257v1.49","unstructured":"Latent Class Technical Paper (2021)."},{"key":"2026021814001023000_2026.02.13.26346257v1.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.04.004"},{"key":"2026021814001023000_2026.02.13.26346257v1.51","unstructured":"Orme B. Consistency Cutoffs to Identify \u201cBad\u201d Respondents in CBC, ACBC, and MaxDiff."},{"key":"2026021814001023000_2026.02.13.26346257v1.52","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-022-03964-3"},{"key":"2026021814001023000_2026.02.13.26346257v1.53","doi-asserted-by":"publisher","DOI":"10.1177\/2325958220981265"},{"key":"2026021814001023000_2026.02.13.26346257v1.54","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-025-10546-w"},{"key":"2026021814001023000_2026.02.13.26346257v1.55","unstructured":"HIV Epidemiology Program. HIV Surveillance Annual Report, 2022 2023. November, 2023. https:\/\/www.nyc.gov\/assets\/doh\/downloads\/pdf\/dires\/hiv-surveillance-annualreport-2022.pdf"},{"key":"2026021814001023000_2026.02.13.26346257v1.56","unstructured":"National Center for HIV VH, STD, and Tuberculosis Prevention,,. HV Surveillance Supplemental Report: Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data United States and 6 Territories and Freely Associated States, 2022. 2024. 05\/21\/2024. https:\/\/stacks.cdc.gov\/view\/cdc\/156511"},{"issue":"3","key":"2026021814001023000_2026.02.13.26346257v1.57","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1093\/cid\/ciac631","article-title":"First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable Human Immunodeficiency Virus (HIV) viremia in an urban HIV clinic","volume":"76","year":"2023","journal-title":"Clinical Infectious Diseases"},{"key":"2026021814001023000_2026.02.13.26346257v1.58","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac455"},{"key":"2026021814001023000_2026.02.13.26346257v1.59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1728-4465.1999.00028.x"},{"key":"2026021814001023000_2026.02.13.26346257v1.60","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-017-1783-9"},{"key":"2026021814001023000_2026.02.13.26346257v1.61","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30258-3"},{"key":"2026021814001023000_2026.02.13.26346257v1.62","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-017-1871-x"},{"key":"2026021814001023000_2026.02.13.26346257v1.63","doi-asserted-by":"publisher","DOI":"10.1177\/088740341305805s03"},{"key":"2026021814001023000_2026.02.13.26346257v1.64","unstructured":"The LATITUDE study: long-acting therapy to improve treatment success in daily life. CinicalTrials.gov. Accessed April 5, 2024, 2024. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03635788"},{"key":"2026021814001023000_2026.02.13.26346257v1.65","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab439"},{"key":"2026021814001023000_2026.02.13.26346257v1.66","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00136-4"},{"key":"2026021814001023000_2026.02.13.26346257v1.67","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002466"},{"key":"2026021814001023000_2026.02.13.26346257v1.68","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003661"},{"key":"2026021814001023000_2026.02.13.26346257v1.69","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.8.890"},{"key":"2026021814001023000_2026.02.13.26346257v1.70","doi-asserted-by":"publisher","DOI":"10.1136\/bmjsrh-2017-200037"},{"key":"2026021814001023000_2026.02.13.26346257v1.71","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-018-6122-1"},{"key":"2026021814001023000_2026.02.13.26346257v1.72","first-page":"1053","article-title":"How well do discrete choice experiments predict health choices? A systematic review and meta-analysis of external validity","volume":"9","year":"2018","journal-title":"The European Journal of Health Economics"},{"key":"2026021814001023000_2026.02.13.26346257v1.73","doi-asserted-by":"publisher","DOI":"10.1097\/coh.0000000000000166"},{"key":"2026021814001023000_2026.02.13.26346257v1.74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190487"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.02.13.26346257","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T22:00:22Z","timestamp":1771452022000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.02.13.26346257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":74,"URL":"https:\/\/doi.org\/10.64898\/2026.02.13.26346257","relation":{},"subject":[],"published":{"date-parts":[[2026,2,16]]},"subtype":"preprint"}}